New Inhibitors for Urokinase-type Plasminogen Activator
Author Information
Author(s): Heynekamp Justin J, Hunsaker Lucy A, Vander Jagt Thomas A, Deck Lorraine M, Vander Jagt David L
Primary Institution: University of New Mexico
Hypothesis
Can uncharged isocoumarin-based compounds serve as effective inhibitors of urokinase-type plasminogen activator (uPA)?
Conclusion
The study shows that uncharged inhibitors of uPA can be developed using an isocoumarin scaffold, with specific structural features enhancing their binding.
Supporting Evidence
- 4-Chloro-3-alkoxyisocoumarins were synthesized and tested for their ability to inhibit uPA.
- N- [3-(3-Bromopropoxy)-4-chloro-1-oxo-1H-isochromen-7-yl]benzamide was identified as a potent uncharged lead inhibitor.
- The introduction of a bromine atom in the three position of the isocoumarin scaffold improved binding.
- Compounds with a benzamide group in the seven position showed significantly improved binding to uPA.
Takeaway
Scientists created new medicines that can stop a protein involved in cancer from working, using a special chemical structure that doesn't have a charge.
Methodology
The study involved synthesizing various uncharged isocoumarin compounds and testing their effectiveness as uPA inhibitors through molecular modeling and dissociation constant measurements.
Limitations
The study did not address the specificity of the inhibitors for uPA compared to other proteases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website